Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
13
JAGX Quote, Financials, Valuation and Earnings
Last price:
$1.09
Seasonality move
:
107.52%
Day range:
$1.00 - $1.10
52-week range:
$1.01 - $33.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.08x
P/B ratio:
0.41x
Volume:
376.5K
Avg. volume:
181K
1-year change:
-95.96%
Market cap:
$1.3M
Revenue:
$11.7M
EPS (TTM):
-$52.01
Analysts' Opinion
-
Consensus RatingJaguar Health, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.50, Jaguar Health, Inc. has an estimated upside of 2400% from its current price of $1.02.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $1.02.
Fair Value
-
According to the consensus of 1 analyst, Jaguar Health, Inc. has 2400% upside to fair value with a price target of $25.50 per share.
JAGX vs. S&P 500
-
Over the past 5 trading days, Jaguar Health, Inc. has underperformed the S&P 500 by -17.75% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Jaguar Health, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Jaguar Health, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Jaguar Health, Inc. reported revenues of $3.1M.
Earnings Growth
-
Jaguar Health, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Jaguar Health, Inc. reported earnings per share of -$6.28.
Enterprise value:
30.9M
EV / Invested capital:
0.85x
Price / LTM sales:
0.08x
EV / EBIT:
--
EV / Revenue:
2.62x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-1.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$7.4M
Return On Assets:
-78.59%
Net Income Margin (TTM):
-348.22%
Return On Equity:
-524.57%
Return On Invested Capital:
-97.4%
Operating Margin:
-234.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $10.7M | $10.5M | $11.8M | $3.1M | $3.1M | |
| Gross Profit | $7.1M | $6M | $7.4M | $2M | $2M | |
| Operating Income | -$33M | -$29.9M | -$32.8M | -$7.3M | -$7.2M | |
| EBITDA | -$30.6M | -$27.5M | -$30.6M | -$6.7M | -$6.7M | |
| Diluted EPS | -$412.92 | -$16.10 | -$52.01 | -$1.05 | -$6.28 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $24M | $25.2M | $22.1M | $36.6M | $29.4M | |
| Total Assets | $59.3M | $51.3M | $45.4M | $58.5M | $49.5M | |
| Current Liabilities | $12M | $26.9M | $12.5M | $19.9M | $36.1M | |
| Total Liabilities | $37.7M | $47.7M | $44M | $42.9M | $45.1M | |
| Total Equity | $21.6M | $3.6M | $1.4M | $15.6M | $4.4M | |
| Total Debt | $25.8M | $32.5M | $35M | $33.9M | $31.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$32.2M | -$29M | -$26M | -$6.3M | -$4.7M | |
| Cash From Investing | $866K | -$10K | -$269K | -- | -$54K | |
| Cash From Financing | $24M | $39M | $16.7M | $3.5M | $6.3M | |
| Free Cash Flow | -$32.6M | -$29M | -$26.3M | -$6.3M | -$4.7M | |
JAGX
Sector
Market Cap
$1.3M
$28.4M
Price % of 52-Week High
3.07%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-460.4%
-1.32%
1-Year Price Total Return
-95.96%
-22.19%
Beta (5-Year)
-0.122
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.21
200-day SMA
Sell
Level
$4.63
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$1.48
Relative Strength Index (RSI14)
Sell
Level
31.88
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-98.9691
50-day SMA
Sell
Level
$1.85
MACD (12, 26)
Sell
Level
-0.21
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.2709)
Sell
CA Score
(Annual)
Level (-4.6921)
Buy
Beneish M-Score
(Annual)
Level (-3.4947)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.9083)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
Stock Forecast FAQ
In the current month, JAGX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The JAGX average analyst price target in the past 3 months is $25.50.
-
Where Will Jaguar Health, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Jaguar Health, Inc. share price will rise to $25.50 per share over the next 12 months.
-
What Do Analysts Say About Jaguar Health, Inc.?
Analysts are divided on their view about Jaguar Health, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Jaguar Health, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Jaguar Health, Inc.'s Price Target?
The price target for Jaguar Health, Inc. over the next 1-year time period is forecast to be $25.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is JAGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Jaguar Health, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of JAGX?
You can purchase shares of Jaguar Health, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Jaguar Health, Inc. shares.
-
What Is The Jaguar Health, Inc. Share Price Today?
Jaguar Health, Inc. was last trading at $1.09 per share. This represents the most recent stock quote for Jaguar Health, Inc.. Yesterday, Jaguar Health, Inc. closed at $1.02 per share.
-
How To Buy Jaguar Health, Inc. Stock Online?
In order to purchase Jaguar Health, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get JAGX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
JAGX
Sector
P/E ratio
--
23.66x
PEG ratio
0.00x
-0.01x
P/B ratio
0.41x
1.84x
Price / LTM sales
0.08x
1.60x
Growth Metrics
JAGX
Sector
Revenue growth
-0.8%
4.85%
Earnings growth
-497.14%
11.15%
Revenue (5-year growth)
15.14%
6.45%
Earnings forecast
-$5.08
-$0.20
Profitability
JAGX
Sector
Profitability FY 2024
$7.4M
$3.6M
Return on invested capital
-97.4%
-30.98%
Return on assets
-78.59%
-27.62%
Return on equity
-524.57%
-36.69%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
13
Balance Sheet
JAGX
Sector
Total cash
$3.5M
$27.2M
Short term investments
--
$25.7M
Total assets
$53.4M
$79.9M
Long term debt
$31.7M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
